Meet ApplyKite Twin, the application assistant that learns with you

Meet your Twin, it learns with you

Your Twin learns with you

Launch week codes:30% off annual Pro20% off monthly Pro

Ends in00h00m00s

Edward Cliff

Peter MacCallum Cancer Institute

Australia

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Professors in Australia Professors in Immunology Immunology professors in Australia

Articles (20)

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Collaborators (5)

Talal Hilal

Assistant Professor of Medicine

University of Mississippi Medical Center

UNITED STATES

View details

Anthony Jeffrey

Clinical Associate Lecturer

University of Sydney

AUSTRALIA

View details

David A. Russler-Germain

Washington University School of Medicine

UNITED STATES

View details

Martin Kaiser

Professor of Haematology

The Institute of Cancer Research & The Royal Marsden NHS Foundation Trust

UNITED KINGDOM

View details

Ajay Major

Assistant Professor of Medicine

University of Colorado School of Medicine

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Edward Cliff

Research Interests

Make your next move.

Explore related searches

Articles (20)

Tumultuous Development of Venetoclax in t(11;14) Multiple Myeloma

Ciltacabtagene autoleucel heralds the arrival of fixed-duration therapies in myeloma

Does ciltacabtagene autoleucel have a future in multiple myeloma?

Clinical trials portfolio and regulatory outcomes of ixazomib in multiple myeloma: A systematic review and meta‐analysis

Immunosuppression-Associated Peripheral T-Cell Lymphoma

Choosing between Nivo‐AVD and BrECADD: Hodgkin lymphoma's new era

Time of infusion does not significantly impact outcomes following CAR T-cell therapy in large B-cell lymphoma

Global access to commercial CAR T-cell therapies: a cross-sectional study of health technology assessment across the G20 countries

Optimizing Control Arms in Chronic Lymphocytic Leukemia Clinical Trials: The BRUIN-CLL-321 Trial

Cell-of-Origin Subtype Predicts Response to Polatuzumab Vedotin in Large B-cell Lymphoma

Outcomes of Nononcology Accelerated Approvals—Reply

Optimizing oncology drug development: systematic review of 22 years of myeloma randomized controlled trials

Discovering a transformative cancer drug: The case of ibrutinib

Reproductive Considerations of Gene Therapies for Sickle Cell Disease and Beta-Thalassemia

Regulatory and Clinical Outcomes of Nononcology Accelerated Approvals

Reducing Drug Prices—The Most Favored Nation Policy vs Price Negotiation

Patient Preferences on Clinical Decision Making in Multiple Myeloma

Medicare spending and use of subcutaneous biologic formulations with hyaluronidase

Beyond maximum grade: tolerability of immunotherapies, cellular therapies, and targeted agents in haematological malignancies

Predictors of withdrawal of anticancer drug indications granted accelerated approval: a retrospective cohort study

Collaborators (5)

Talal Hilal

Anthony Jeffrey

David A. Russler-Germain

Martin Kaiser

Ajay Major

Make your next move.